JOELLE RANKIN: Open Payments
NPI 1447723416 · ORANGE CITY, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$862 in 36 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $1,203 · 2025 $862
Food & beverage: $778Education: $84
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $202 |
| Madrigal Pharmaceuticals | 8 | $169 |
| Janssen Biotech, Inc. | 3 | $127 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $82 |
| Phathom Pharmaceuticals, Inc. | 2 | $78 |
| Gilead Sciences, Inc. | 3 | $72 |
| ABBVIE INC. | 2 | $46 |
| GENZYME CORPORATION | 2 | $38 |
| Lilly USA, LLC | 1 | $30 |
| Intercept Pharmaceuticals, Inc. | 1 | $17 |
Products named: REZDIFFRA, ENTYVIO, TREMFYA, XIFAXAN, VOQUEZNA, EOHILIA, DUPIXENT, OMVOH.
Industry payments across FL — which companies pay providers there.
